Nemolizumab Therapeutic Cheat Sheet
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …
As dermatologists, we recognize that chronic itch is a complex and often debilitating condition that significantly impacts our patients' quality of life, affecting their physical health, mental well-being, and daily activities. Chronic itch can be especially challenging to diagnose and treat, particularly in patients with skin of color, who may experience unique clinical manifestations and complic …
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Shawn Kwatra, associate professor of dermatology at Johns Hopkins University School of Medicine. Watch and learn Dr. Kwatra’s tips for a workup in an itchy patient. Itch falls on the neuroimmune spectrum, so learn why it’s important to determine if a dermatological condition is to bl …
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Shawn Kwatra, associate professor of dermatology at Johns Hopkins University School of Medicine. Dr. Kwatra shares what dermatology clinicians need to know about racial disparities in itch. Find out how disease prevalence and presentation play a role in these disparities. Watch as Dr. Kw …
Atopic dermatitis is a heterogeneous, chronic inflammatory disease that affects upwards of 10% of children and 7% of adults in the United States. Despite being an incredibly common skin concern among patients, AD continues to pose diagnostic and treatment challenges to dermatologists.
What are some common misconceptions about AD?
AD always starts in childhood. FALSE. 25% of adults w …